Department of Population Health Sciences, Duke University School of Medicine, Durham, North Carolina, USA.
Duke Clinical Research Institute, Durham, North Carolina, USA.
J Am Med Inform Assoc. 2022 Apr 13;29(5):798-804. doi: 10.1093/jamia/ocac004.
To empirically explore how pragmatic clinical trials (PCTs) that used real-world data (RWD) assessed study-specific fitness-for-use.
We conducted interviews and surveys with PCT teams who used electronic health record (EHR) data to ascertain endpoints. The survey cataloged key concerns about RWD, activities used to assess data fitness-for-use, and related barriers encountered by study teams. Patterns and commonalities across trials were used to develop recommendations for study-specific fitness-for-use assessments.
Of 15 invited trial teams, 7 interviews were conducted. Of 31 invited trials, 15 responded to the survey. Most respondents had prior experience using RWD (93%). Major concerns about EHR data were data reliability, missingness or incompleteness of EHR elements, variation in data quality across study sites, and presence of implausible or incorrect values. Although many PCTs conducted fitness-for-use activities (eg, data quality assessments, 11/14, 79%), less than a quarter did so before choosing a data source. Fitness-for-use activities, findings, and resulting study design changes were not often publically documented. Overall costs and personnel costs were barriers to fitness-for-use assessments.
These results support three recommendations for PCTs that use EHR data for endpoint ascertainment. Trials should detail the rationale and plan for study-specific fitness-for-use activities, conduct study-specific fitness-for-use assessments early in the prestudy phase to inform study design changes before the trial begins, and share results of fitness-for-use assessments and description of relevant challenges and facilitators.
These recommendations can help researchers and end-users of real-world evidence improve characterization of RWD reliability and relevance in the PCT-specific context.
从实证角度探讨使用真实世界数据(RWD)的实用临床试验(PCT)如何评估研究特定适用性。
我们对使用电子健康记录(EHR)数据确定终点的 PCT 团队进行了访谈和调查。该调查记录了对 RWD 的关键关注、用于评估数据适用性的活动以及研究团队遇到的相关障碍。试验之间的模式和共性用于制定研究特定适用性评估的建议。
在 15 个受邀试验团队中,进行了 7 次访谈。在 31 个受邀试验中,有 15 个对调查做出了回应。大多数受访者之前都有使用 RWD 的经验(93%)。对 EHR 数据的主要担忧是数据可靠性、EHR 要素的缺失或不完整、研究地点之间数据质量的差异以及存在不合理或不正确的值。尽管许多 PCT 进行了适用性活动(例如,数据质量评估,11/14,79%),但不到四分之一的活动是在选择数据源之前进行的。适用性活动、发现和由此产生的研究设计变更通常没有公开记录。总体成本和人员成本是适用性评估的障碍。
这些结果支持了使用 EHR 数据进行终点确定的 PCT 的三项建议。试验应详细说明研究特定适用性活动的理由和计划,在研究前阶段尽早进行研究特定适用性评估,以便在试验开始之前为研究设计变更提供信息,并分享适用性评估的结果以及相关挑战和促进因素的描述。
这些建议可以帮助真实世界证据的研究人员和最终用户在 PCT 特定背景下更好地描述 RWD 的可靠性和相关性。